Latest Breaking News On - Steve fruchtman - Page 1 : comparemela.com

Onconova Therapeutics Preclinical Narazaciclib Data at SABCS Highlights Differentiated | Region

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors

Mark guerinBruce mackleSteve fruchtmanSecurities exchangeCompany contactLifesci advisorsOnconova therapeutics incSan antonio breast cancer symposiumChief executiveOnconova therapeuticsSecurities actSecurities exchange actPrivate securities litigation reform actAnnual reportSci advisors

Onconova Therapeutics (ONTX) Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v Other CDK4/6i s

Onconova Therapeutics (ONTX) Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v Other CDK4/6i s
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Steve fruchtmanOnconova therapeutics incOnconova therapeuticsSan antonio breast cancer symposiumChief executive

Onconova Therapeutics, Inc (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.

United statesSan antonioCharles zhuVictor moyoThomas jeffersonMeena aroraEdouard mullarkyBruce mackleMark guerinSteve fruchtmanMost valuable mining companiesAmerican society for hematologyLadenburg thalmannEuropean network for gynecologic oncology trialsGlobal medical affairs researchGynecologic oncology group

Onconova Therapeutics, Inc (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript August 10, 2023 Onconova Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.29. Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman: Sarah, excuse me, you are coming in and out […]

New yorkUnited statesMark guerinPangea biomedSteve fruchtmanVictor moyoInternational society of investigative dermatologyInternational epidermolysis bullosa symposiumIcahn school of medicine at mount sinaiVanderbilt universityInternational societyInvestigative dermatologyIcahn schoolMount sinaiSquamous cell carcinomaOnconova therapeutics

Onconova Therapeutics, Inc (ONTX) CEO Steve Fruchtman on Q2 2022 Results - Earnings Call Transcript

Onconova Therapeutics, Inc. (NASDAQ:NASDAQ:ONTX) Q2 2022 Earnings Conference Call August 11, 2022 16:30 ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Steve.

Lung chunUnited statesFrance generalRobert leboyerSteve fruchtmanAdar makovski silversteinMark guerinMark gelderBruce mackleCharles zhuCompany participantsEuropean society of medical oncologyAmerican society of clinical oncologyLadenburg thalmannHead of corporate developmentAmerican society of clinical oncology annual meeting